Paul Tudor Jones Dermata Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
BUY
$374.4 - $1500.0 $3.82 Million - $15.3 Million
10,205 New
10,205 $18,000

Others Institutions Holding DRMA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Dermata Therapeutics, Inc.

DRMA Quotes by TradingView
  • Ticker DRMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,102,200
  • Market Cap $13.5M
  • Description
  • Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...
More about DRMA
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email